［1］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73:17-48.
［2］DESANTIS CE,MA J,GAUDET MM,et al.Breast cancer statistics,2019［J］.CA Cancer J Clin,2019,69(6):438-451.
［3］陈茜,张频.乳腺癌内分泌治疗耐药机制及临床研究进展［J］.中华肿瘤防治杂志,2021,28(8):555-561.
CHEN X，ZHANG P.Mechanisms of emdocrine resisitant for breast cancer and advances in clinical studies［J］.Chinese Journal of Cancer Prevention and Treatment,2021,28(8):555-561.
［4］YANG L,SHI P,ZHAO G,et al.Targeting cancer stem cell pathways for cancer therapy［J］.Signal Transduct Target Ther,2020,5(1):8.
［5］AL-HAJJ M,WICHA MS,BENITO-HERNANDEZ A,et al.Prospective identification of tumorigenic breast cancer cells［J］.Proceedings of the National Academy of Sciences of the United States of America,2003,100(7):3983-3988.
［6］GINESTIER C,HUR MH,CHARAFE-JAUFFRET E,et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome［J］.Cell Stem Cell,2007,1(5):555-567.
［7］SONG K,FARZANEH M.Signaling pathways governing breast cancer stem cells behavior［J］.Stem Cell Res Ther,2021,12(1):245.
［8］GOODING AJ,SCHIEMANN WP.Epithelial-mesenchymal transition programs and cancer stem cell phenotypes:Mediators of breast cancer therapy resistance［J］.Molecular Cancer Research,2020,18(9):1257-1270.
［9］WANG X,WANG G,ZHAO Y,et al.STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro［J］.J Biomed Res,2012,26(5):325-335.
［10］LIU H,ZHANG HW,SUN XF,et al.Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties［J］.Chinese Medical Journal,2013,126(16):3030-3034.
［11］ATTIA YM,SALAMA SA,SHOUMAN SA,et al.Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer［J］.Pharmacol Rep,2022,74(2):366-378.
［12］RAFFO D,BERARDI DE,PONTIGGIA O,et al.Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate［J］.Breast Cancer Research and Treatment,2013,142(3):537-548.
［13］SIMOES BM,O'BRIEN CS,EYRE R,et al.Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity［J］.Cell Reports,2015,12(12):1968-1977.
［14］GUTIERREZ MC,DETRE S,JOHNSTON S,et al.Molecular changes in tamoxifen-resistant breast cancer:Relationship between estrogen receptor,HER-2,and p38 mitogen-activated protein kinase［J］.Journal of Clinical Oncology,2005,23(11):2469-2476.
［15］GELSOMINO L,PANZA S,GIORDANO C,et al.Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines［J］.Cancer Letters,2018,428:12-20.
［16］LEI JT,SHAO J,ZHANG J,et al.Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer［J］.Cell Reports,2018,24(6):1434-1444,e1437.
［17］LIU XY,MA D,XU XE,et al.Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive,progesterone receptor-negative,and HER2-negative breast cancer［J］.Theranostics,2018,8(22):6386-6399.
［18］JEONG Y,BAE SY,YOU D,et al.EGFR is a therapeutic target in hormone receptor-positive breast cancer［J］.Cellular Physiology and Biochemistry,2019,53(5):805-819.
［19］KIM CY,KIM YC,OH JH,et al.HOXB5 confers tamoxifen resistance in breast cancer cells and promotes tumor aggression and progression［J］.Anticancer Research,2021,41(7):3409-3417.
［20］MONTASER RZ,COLEY HM.Crosstalk between ERα and receptor tyrosine kinase signalling and implications for the development of anti-endocrine resistance［J］.Cancers,2018,10(6):209.
［21］MOSSAHEBI-MOHAMMADI M,QUAN M,ZHANG JS,et al.FGF signaling pathway:A key regulator of stem cell pluripotency［J］.Frontiers in Cell and Developmental Biology,2020,8:79.
［22］FORMISANO L,LU Y,SERVETTO A,et al.Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer［J］.Nature Communications,2019,10(1):1373.
［23］DWYER AR,TRUONG TH,KERKVLIET CP,et al.Insulin receptor substrate-1（IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer［J］.British Journal of Cancer,2021,124(1):217-227.
［24］IIDA M,TSUBOI K,NIWA T,et al.Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer［J］.Breast Cancer（Tokyo,Japan),2019,26(3):272-281.
［25］POMMIER SJ,HERNANDEZ A,HAN E,et al.Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities［J］.Annals of Surgical Oncology,2012,19(2):527-535.
［26］LI X,ZHOU N,WANG J,et al.Quercetin suppresses breast cancer stem cells CD44+/CD24- by inhibiting the PI3K/Akt/mTOR-signaling pathway［J］.Life Sciences,2018,196:56-62.
［27］KARTHIK GM,MA R,LOVROT J,et al.mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells［J］.Cancer Letters,2015,367(1):76-87.
［28］LIU Y,ZHANG XB,LIU JJ,et al.NVP-BKM120 in combination with letrozole inhibit human breast cancer stem cells via PI3K/mTOR pathway［J］.Chinese Medical Journal,2019,99(14):1075-1080.
［29］KIM CY,KIM YC,OH JH,et al.HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer［J］.Journal of Cancer,2021,12(15):4626-4637.
［30］FUKUI F,HAYASHI SI,YAMAGUCHI Y.Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy［J］.The Journal of Steroid Biochemistry and Molecular Biology,2020,201:105698.
［31］陈伟玲,张永渠,李瑶琛,等.Notch和Wnt信号通路及两者的交叉串话与乳腺癌发生、发展的关系［J］.中华乳腺病杂志（电子版）,2019,13(4):245-248.
CHEN WL,ZHANG YQ,LI YC,et al.The relationship between Notch and Wnt signal pathway and their cross talk with the occurrence and development of breast cancer［J］.Chinese Journal of Breast Disease(Electronic Edition),2019,13(4):245-248.
［32］SHAO S,ZHAO X,ZHANG X,et al.Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner［J］.Molecular Cancer,2015,14(1):28.
［33］MCCLEMENTS L,ANNETT S,YAKKUNDI A,et al.FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4［J］.BMC Cancer,2019,19(1):351.
［34］RIZZO P,MIAO H,D'SOUZA G,et al.Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches［J］.Cancer research,2008,68(13):5226-5235.
［35］PEIFFER DS,WYATT D,ZLOBIN A,et al.DAXX suppresses tumor-initiating cells in estrogen receptor-positive breast cancer following endocrine therapy［J］.Cancer Research,2019,79(19):4965-4977.
［36］ANGELONI V,TIBERIO P,APPIERTO V,et al.Implications of stemness-related signaling pathways in breast cancer response to therapy［J］.Seminars in Cancer Biology,2015,31:43-51.
［37］HARDT O,WILD S,OERLECKE I,et al.Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing:Evidence for a hyperactive PI3K pathway［J］.Cancer Letters,2012,325(2):165-174.
［38］LOH YN,HEDDITCH EL,BAKER LA,et al.The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer［J］.BMC Cancer,2013,13:174.
［39］LEUNG EY,ASKARIAN-AMIRI ME,SARKAR D,et al.Endocrine therapy of estrogen receptor-positive breast cancer cells:Early differential effects on stem cell markers［J］.Frontiers in Oncology,2017,7:184.
［40］DOMENICI G,AURREKOETXEA-RODRIGUEZ I,SIMOES BM,et al.A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells［J］.Oncogene,2019,38(17):3151-3169.
［41］JANG GB,HONG IS,KIM RJ,et al.Wnt/beta-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells［J］.Cancer Research,2015,75(8):1691-1702.
［42］SAKUNRANGSIT N,KETCHART W.Plumbagin inhibits cancer stem-like cells,angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer［J］.Pharmacological Research,2019,150:104517.
［43］MOROISHI T,HANSEN CG,GUAN KL.The emerging roles of YAP and TAZ in cancer［J］.Nature Reviews Cancer,2015,15(2):73-79.
［44］CORDENONSI M,ZANCONATO F,AZZOLIN L,et al.The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells［J］.Cell,2011,147(4):759-772.
［45］KULKARNI M,TAN TZ,SYED SULAIMAN NB,et al.RUNX1 and RUNX3 protect against YAP-mediated EMT,stem-ness and shorter survival outcomes in breast cancer［J］.Oncotarget,2018,9(18):14175-14192.
［46］BARTUCCI M,DATTILO R,MORICONI C,et al.TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells［J］.Oncogene,2015,34(6):681-690.
［47］LI J,FENG X,LI C,et al.Downregulation of WW domain-containing oxidoreductase leads to tamoxifen-resistance by the inactivation of Hippo signaling［J］.Exp Biol Med（Maywood),2019,244(12):972-982.
［48］BRITSCHGI A,DUSS S,KIM S,et al.The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα［J］.Nature,2017,541(7638):541-545.
［49］CHEN J,WAN R,LI Q,et al.Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer［J］.Cancer Cell International,2021,21(1):306.
［50］DAS PK,SIDDIKA MA,ASHA SY,et al.MicroRNAs,a promising target for breast cancer stem cells［J］.Mol Diagn Ther,2020,24(1):69-83.
［51］BAHENA-OCAMPO I,ESPINOSA M,CEBALLOS-CANCINO G,et al.miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation［J］.EMBO Reports,2016,17(5):648-658.
［52］SUN X,XU C,XIAO G,et al.Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking［J］.International Journal of Molecular Medicine,2018,41(4):1967-1975.
［53］WEI Y,LI H,QU Q.miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers［J］.Breast Cancer（Tokyo,Japan),2021,28(1):175-186.
［54］MEANS-POWELL JA,MAYER IA,ISMAIL-KHAN R,et al.A phase Ib dose escalation trial of RO4929097（a γ-secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer（MBC)［J］.Clinical Breast Cancer,2022,22(2):103-114.
［55］LIU J,LI J,CHEN H,et al.Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway［J］.Journal of Cellular and Molecular Medicine,2020,24(10):5786-5796.
［56］DENT S,CORTES J,IM YH,et al.Phase Ⅲ randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive,PIK3CA-mutant,HER2-negative,advanced breast cancer:The SANDPIPER trial［J］.Annals of Oncology,2021,32(2):197-207.